The U.S. opportunity must be translated from relevant patient populations into addressable WGS testing segments
Clinical-population context—not WGS market size.
Selected U.S. hematological-malignancy incidence context, 2026
- Relevant populationLeukemia, NHL and multiple myeloma incidence context
- Eligible testing populationValue pending validation
- Current testing workflowValue pending validation
- Potential WGS adoptionValue pending validation
- Addressable marketValue pending validation
Report segmentation
- Testing sites
- Technology and informatics providers
- Pharmaceutical partners
- Payers and regulators
10-Year U.S. Market Outlook
The full BIS Research engagement will provide a 10-year forecast segmented by indication, offering, use setting and end user.
Validated U.S. market sizing and the 10-year forecast are available with full bis research access.
Invivoscribe implication
Disease incidence establishes the clinical context, but the commercial opportunity depends on testing eligibility, adoption and customer readiness.
Recommended action
Build the U.S. market model from indication-level testing pathways rather than applying a broad WGS market estimate.